液基薄层细胞学检查联合人乳头瘤病毒E6/E7 mRNA检测在宫颈病变筛查中的价值分析

doi:10.3969/j.issn.1006-7795.2019.04.016

摘要/Abstract

摘要： 目的探讨薄层液基细胞学检查（thinprep cytology test，TCT）联合人乳头瘤病毒（human papillomavirus，HPV） E6/E7 mRNA检测在宫颈疾病筛查中的应用效果。方法选取538例患者作为研究对象，所有患者均行TCT、HPV E6/E7检测和阴道镜下宫颈多点活检，比较单独使用TCT或HPV E6/E7 mRNA以及联合TCT和HPV E6/E7 mRNA检测在宫颈病变筛查中的诊断价值。结果以病理学检查作为检测金标准，TCT和HPV E6/E7这两种检测方法对于宫颈病变均具有一定的筛检率，TCT检测的灵敏度66.56%，特异度为53.57%，HPV E6/E7 mRNA检测的灵敏度74.84%，特异度为77.68%，TCT联合HPV E6/E7 mRNA检测的灵敏度和特异度分别为99.68%和39.29%。结论 TCT联合HPV E6/E7 mRNA检测在宫颈病变筛查中可大幅度提高灵敏度，降低临床漏诊率，具有临床筛查价值。

关键词: 薄层液基细胞学检查, 人乳头瘤病毒E6/E7 mRNA, 宫颈疾病

Abstract: Objective To investigate the application value of thinprep cytology test (TCT) combined with human papillomavirus (HPV)E6/E7 mRNA detection in cervical disease screening.Methods A total of 538 cases were detected with gynecological disorders received TCT,HPV E6/E7 and colposcopy cervical biopsy. To compare the diagnostic value of TCT or HPV E6/E7 mRNA alone with combined TCT and HPV E6/E7 mRNA in cervical lesion screening. Results Compared with pathological examination for cervical disease diagnosis, the sensitivity and specificity of TCT was 66.56% and 53.57% respectively, the sensitivity and specificity of HPV E6/E 7 mRNA was 74.84% and 77.68% respectively while the sensitivity and specificity of joint detection of TCT and HPV E6/E7 mRNA was 99.68% and 39.29% respectively. Conclusion The joint detection of TCT and HPV E6/E7 mRNA raises the sensitivity remarkably in cervical disease screening, reduces missed clinic diagnosis rate and contributes to clinic cervical disease screening.

Key words: thinprep cytology test (TCT), human papillomavirus (HPV)E6/E7 mRNA, cervical disease

中图分类号:

王俊飞, 沈树娜, 祝平. 液基薄层细胞学检查联合人乳头瘤病毒E6/E7 mRNA检测在宫颈病变筛查中的价值分析[J]. 首都医科大学学报, 2019, 40(4): 578-581.

Wang Junfei, Shen Shuna, Zhu Ping. Application value of detection of thinprep cytology test and human papillomavirus E6/E7 mRNA in cervical disease screening[J]. Journal of Capital Medical University, 2019, 40(4): 578-581.

参考文献 15

[1]	Peter M,Stransky N,Couturier J,et al. Frequent genomic structural alterations at HPV insertion sites in cervical carcinoma[J].J Pathol,2010,221(3):320-330.
[2]	郑嵘,徐真.TCT联合DNA倍体细胞检测在宫颈癌筛查中的应用效果[J].实用癌症杂志,2015,30(7):967-969.
[3]	Al-Kholy A F,Abdullah O A,Abadier M Z,et al. Pre-treatment serum inflammatory cytokines as survival predictors of patients with nasopharyngeal carcinoma receiving chemoradiotherapy[J]. Mol Clin Oncol,2016,5(6):811-816.
[4]	Lin C T,Qiu J T,Wang C J,et al.Topical imiquimod treatment for human papillomavirus infection in Patients with and without cervical/vaginal intraepithelial neoplasia[J].Taiwan J Obstet Gynecol,2012,5l(4):533-538.
[5]	Scholl S M,Kamal M,De Koning L,et al. HPV Pathway profiling:HPV related cervical dysplasia and carcinoma studies[J]. Curr Pharm Des,2013,19(8):1379-1394
[6]	陈炎添,陈青龙,熊燕,等. HR-HPV DNA PCR联合TCT检测对宫颈癌前病变的诊断价值[J]. 检验医学,2013,28(6):516-518.
[7]	魏萌. 探讨人乳头瘤病毒DNA分型检测联合宫颈液基薄层细胞学检查在宫颈癌筛查诊断中的作用[J].中国妇幼保健,2016,31(16):3264-3266.
[8]	Karimi-Zarchi M,Peighmbari F,Karimi N,et al. A comparison of 3 ways of conventional pap smear,liquid-based cytology and colposcopy vs cervical biopsy for early diagnosis of premalignant lesions or cervical cancer in women with abnormal conventional pap test[J].Int J Biomed Sci,2013,9(4):205-210
[9]	Pan Q J,Hu S Y,Zhang X,et al. Pooled analysis of the performance ofliquid -based cytology in population-based cervical cancer screening studies in China[J].Cancer Cytopathol,2013,121(9):473-482.
[10]	张文晶,刘志强.宫颈癌筛查现状及其应用现状[J].医学综述,2017,23(9):1732-1736
[11]	Munkhdelger J,Choi Y,Lee D,et al. Comparison of the performance of theNucliSENS EasyQ HPV E6/E7 mRNA assay and HPV DNA chip for testing squamous cell lesions of the uterine cervix[J].Diagn Microbiol Infect Dis,2014,79(4):422-427.
[12]	Chernesky M,Jang D,Gilchrist J,et al. Evaluation of a new APTIMA specimen collection and transportation kit for high-risk humanpap-illomavirus E6/E7 messenger RNA in cervical and vaginal samples[J].Sex Transm Dis,2014,41(6):365-368.
[13]	林爽.王翠峰. HPV E6/E7mRNA检测在宫颈癌中的研究进展[J].现代预防医学,2018,45(3):513-519.
[14]	Pan D, Zhang C Q, Liang Q L, et al. An efficient method that combines the ThinPrep cytologic test with E6/E7 mRNA testing for cervical cancer screening[J]. Cancer Manag Res, 2019,11:4773-4780
[15]	Han L, Husaiyin S, Zhao F, et al. Clinical Value of human papillomavirus E6/E7 mRNA detection in screening for cervical cancerin women positive for human papillomavirus DNA[J].Clin Lab, 2018, 64(9):1363-1371.